Cargando…
Associations Between Amplification (1q) and Prior Cancer in a Real-World De Novo Myeloma Cohort
Genomic biomarkers inform treatment in multiple myeloma (MM), making patient clinical data a potential window into MM biology. We evaluated de novo MM patients for associations between specific MM cytogenetic patterns and prior cancer history. Analyzing a MM real-world dataset, we identified a cohor...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7791628/ https://www.ncbi.nlm.nih.gov/pubmed/33442665 http://dx.doi.org/10.1093/jncics/pkaa111 |
_version_ | 1783633633008943104 |
---|---|
author | Lamont, Elizabeth B Yee, Andrew J Goldberg, Stuart L Siegel, David S Norden, Andrew D |
author_facet | Lamont, Elizabeth B Yee, Andrew J Goldberg, Stuart L Siegel, David S Norden, Andrew D |
author_sort | Lamont, Elizabeth B |
collection | PubMed |
description | Genomic biomarkers inform treatment in multiple myeloma (MM), making patient clinical data a potential window into MM biology. We evaluated de novo MM patients for associations between specific MM cytogenetic patterns and prior cancer history. Analyzing a MM real-world dataset, we identified a cohort of 1769 patients with fluorescent in situ hybridization cytogenetic testing at diagnosis. Of the patients, 241 (0.14) had histories of prior cancer(s). Amplification of the long arm of chromosome 1 [amp(1q)] varied by prior cancer history (0.31 with prior cancer vs 0.24 without; 2-sided P = .02). No other MM translocations, amplifications, or deletions were associated with prior cancers. Amp(1q) and cancer history remained strongly associated in a logistic regression adjusting for patient demographic and disease attributes. The results merit follow-up regarding carcinogenic treatment effects and screening strategies for second malignancies. Broadly, the findings suggest that analyses of patient-level phenotypic-genomic real-world dataset may accelerate cancer research through hypothesis-generating studies. |
format | Online Article Text |
id | pubmed-7791628 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-77916282021-01-12 Associations Between Amplification (1q) and Prior Cancer in a Real-World De Novo Myeloma Cohort Lamont, Elizabeth B Yee, Andrew J Goldberg, Stuart L Siegel, David S Norden, Andrew D JNCI Cancer Spectr Brief Communications Genomic biomarkers inform treatment in multiple myeloma (MM), making patient clinical data a potential window into MM biology. We evaluated de novo MM patients for associations between specific MM cytogenetic patterns and prior cancer history. Analyzing a MM real-world dataset, we identified a cohort of 1769 patients with fluorescent in situ hybridization cytogenetic testing at diagnosis. Of the patients, 241 (0.14) had histories of prior cancer(s). Amplification of the long arm of chromosome 1 [amp(1q)] varied by prior cancer history (0.31 with prior cancer vs 0.24 without; 2-sided P = .02). No other MM translocations, amplifications, or deletions were associated with prior cancers. Amp(1q) and cancer history remained strongly associated in a logistic regression adjusting for patient demographic and disease attributes. The results merit follow-up regarding carcinogenic treatment effects and screening strategies for second malignancies. Broadly, the findings suggest that analyses of patient-level phenotypic-genomic real-world dataset may accelerate cancer research through hypothesis-generating studies. Oxford University Press 2021-01-04 /pmc/articles/PMC7791628/ /pubmed/33442665 http://dx.doi.org/10.1093/jncics/pkaa111 Text en © The Author(s) 2021. Published by Oxford University Press. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Brief Communications Lamont, Elizabeth B Yee, Andrew J Goldberg, Stuart L Siegel, David S Norden, Andrew D Associations Between Amplification (1q) and Prior Cancer in a Real-World De Novo Myeloma Cohort |
title | Associations Between Amplification (1q) and Prior Cancer in a Real-World De Novo Myeloma Cohort |
title_full | Associations Between Amplification (1q) and Prior Cancer in a Real-World De Novo Myeloma Cohort |
title_fullStr | Associations Between Amplification (1q) and Prior Cancer in a Real-World De Novo Myeloma Cohort |
title_full_unstemmed | Associations Between Amplification (1q) and Prior Cancer in a Real-World De Novo Myeloma Cohort |
title_short | Associations Between Amplification (1q) and Prior Cancer in a Real-World De Novo Myeloma Cohort |
title_sort | associations between amplification (1q) and prior cancer in a real-world de novo myeloma cohort |
topic | Brief Communications |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7791628/ https://www.ncbi.nlm.nih.gov/pubmed/33442665 http://dx.doi.org/10.1093/jncics/pkaa111 |
work_keys_str_mv | AT lamontelizabethb associationsbetweenamplification1qandpriorcancerinarealworlddenovomyelomacohort AT yeeandrewj associationsbetweenamplification1qandpriorcancerinarealworlddenovomyelomacohort AT goldbergstuartl associationsbetweenamplification1qandpriorcancerinarealworlddenovomyelomacohort AT siegeldavids associationsbetweenamplification1qandpriorcancerinarealworlddenovomyelomacohort AT nordenandrewd associationsbetweenamplification1qandpriorcancerinarealworlddenovomyelomacohort |